Literature DB >> 11781818

How Vav proteins discriminate the GTPases Rac1 and RhoA from Cdc42.

N Movilla1, M Dosil, Y Zheng, X R Bustelo.   

Abstract

Vav proteins are GDP/GTP exchange factors for Rho/Rac GTPases that are activated by tyrosine phosphorylation. These proteins activate Rac1, RhoG, and RhoA but not the highly related Cdc42 protein. At present, there is no available information to explain this substrate selectivity at the structural level. Here we show that the selection of Vav proteins substrates is achieved at two different levels. On one hand, Vav proteins utilize some residues of the beta2/beta3 region of Rho/Rac GTPases (D49 and E54) to assure the specific binding to its substrate. In addition, these exchange factors need a second structural signal located in the beta5 region of Rho/Rac proteins (residue K118) to promote proper GDP/GTP exchange. These results identify the amino acid residues that allow the discrimination of the Vav family substrates from Cdc42 and, in addition, demonstrate that the activation of specific Rho/Rac GTPases by these GEFs requires two concatenated events, binding and subsequent enzyme reaction, whose specificities are determined by two separate regions of Rho proteins.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11781818     DOI: 10.1038/sj.onc.1205000

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  29 in total

1.  Rational design and characterization of a Rac GTPase-specific small molecule inhibitor.

Authors:  Yuan Gao; J Bradley Dickerson; Fukun Guo; Jie Zheng; Yi Zheng
Journal:  Proc Natl Acad Sci U S A       Date:  2004-05-05       Impact factor: 11.205

Review 2.  Rho GTPases: functions and association with cancer.

Authors:  Saskia I J Ellenbroek; John G Collard
Journal:  Clin Exp Metastasis       Date:  2007-11-14       Impact factor: 5.150

3.  Remedial strategies in structural proteomics: expression, purification, and crystallization of the Vav1/Rac1 complex.

Authors:  Alexei Brooun; Scott A Foster; Jill E Chrencik; Ellen Y T Chien; Anand R Kolatkar; Markus Streiff; Paul Ramage; Hans Widmer; Gisbert Weckbecker; Peter Kuhn
Journal:  Protein Expr Purif       Date:  2006-12-05       Impact factor: 1.650

4.  Characterization of EHop-016, novel small molecule inhibitor of Rac GTPase.

Authors:  Brenda L Montalvo-Ortiz; Linette Castillo-Pichardo; Eliud Hernández; Tessa Humphries-Bickley; Alina De la Mota-Peynado; Luis A Cubano; Cornelis P Vlaar; Suranganie Dharmawardhane
Journal:  J Biol Chem       Date:  2012-03-01       Impact factor: 5.157

Review 5.  Cell growth and metastasis in pancreatic cancer: is Vav the Rho'd to activation?

Authors:  Daniel D Billadeau
Journal:  Int J Gastrointest Cancer       Date:  2002

6.  Asef2 functions as a Cdc42 exchange factor and is stimulated by the release of an autoinhibitory module from a concealed C-terminal activation element.

Authors:  Michael J Hamann; Casey M Lubking; Doris N Luchini; Daniel D Billadeau
Journal:  Mol Cell Biol       Date:  2006-12-04       Impact factor: 4.272

7.  Vav family proteins are required for optimal regulation of PLCgamma2 by integrin alphaIIbbeta3.

Authors:  Andrew C Pearce; Owen J T McCarty; Simon D J Calaminus; Elena Vigorito; Martin Turner; Steve P Watson
Journal:  Biochem J       Date:  2007-02-01       Impact factor: 3.857

8.  Phylogenetic conservation of the regulatory and functional properties of the Vav oncoprotein family.

Authors:  José R Couceiro; María D Martín-Bermudo; Xosé R Bustelo
Journal:  Exp Cell Res       Date:  2005-08-15       Impact factor: 3.905

9.  The gp130 Cytokine Interleukin-11 Regulates Engraftment of Vav1-/- Hematopoietic Stem and Progenitor Cells in Lethally Irradiated Recipients.

Authors:  Serena De Vita; Yanhua Li; Chad E Harris; Meaghan K McGuinness; Clement Ma; David A Williams
Journal:  Stem Cells       Date:  2018-01-10       Impact factor: 6.277

10.  Yersinia enterocolitica targets cells of the innate and adaptive immune system by injection of Yops in a mouse infection model.

Authors:  Martin Köberle; Annegret Klein-Günther; Monika Schütz; Michaela Fritz; Susanne Berchtold; Eva Tolosa; Ingo B Autenrieth; Erwin Bohn
Journal:  PLoS Pathog       Date:  2009-08-14       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.